1637 related articles for article (PubMed ID: 30388409)
1. CRISPR-Based Technologies: Impact of RNA-Targeting Systems.
Terns MP
Mol Cell; 2018 Nov; 72(3):404-412. PubMed ID: 30388409
[TBL] [Abstract][Full Text] [Related]
2. Molecular Mechanisms of RNA Targeting by Cas13-containing Type VI CRISPR-Cas Systems.
O'Connell MR
J Mol Biol; 2019 Jan; 431(1):66-87. PubMed ID: 29940185
[TBL] [Abstract][Full Text] [Related]
3. The Revolution Continues: Newly Discovered Systems Expand the CRISPR-Cas Toolkit.
Murugan K; Babu K; Sundaresan R; Rajan R; Sashital DG
Mol Cell; 2017 Oct; 68(1):15-25. PubMed ID: 28985502
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Cas12 and Cas13: the lesser known siblings of CRISPR-Cas9.
Yan F; Wang W; Zhang J
Cell Biol Toxicol; 2019 Dec; 35(6):489-492. PubMed ID: 31468291
[No Abstract] [Full Text] [Related]
5. Structures, mechanisms and applications of RNA-centric CRISPR-Cas13.
Yang H; Patel DJ
Nat Chem Biol; 2024 Jun; 20(6):673-688. PubMed ID: 38702571
[TBL] [Abstract][Full Text] [Related]
6. Battling CRISPR-Cas9 off-target genome editing.
Li D; Zhou H; Zeng X
Cell Biol Toxicol; 2019 Oct; 35(5):403-406. PubMed ID: 31313008
[No Abstract] [Full Text] [Related]
7. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells.
Hendel A; Bak RO; Clark JT; Kennedy AB; Ryan DE; Roy S; Steinfeld I; Lunstad BD; Kaiser RJ; Wilkens AB; Bacchetta R; Tsalenko A; Dellinger D; Bruhn L; Porteus MH
Nat Biotechnol; 2015 Sep; 33(9):985-989. PubMed ID: 26121415
[TBL] [Abstract][Full Text] [Related]
8. Minimizing off-target effects in CRISPR-Cas9 genome editing.
Chen SJ
Cell Biol Toxicol; 2019 Oct; 35(5):399-401. PubMed ID: 31317359
[No Abstract] [Full Text] [Related]
9. The next generation of CRISPR-Cas technologies and applications.
Pickar-Oliver A; Gersbach CA
Nat Rev Mol Cell Biol; 2019 Aug; 20(8):490-507. PubMed ID: 31147612
[TBL] [Abstract][Full Text] [Related]
10. Editor's cut: DNA cleavage by CRISPR RNA-guided nucleases Cas9 and Cas12a.
Swartjes T; Staals RHJ; van der Oost J
Biochem Soc Trans; 2020 Feb; 48(1):207-219. PubMed ID: 31872209
[TBL] [Abstract][Full Text] [Related]
11. Rapid Control of Genome Editing in Human Cells by Chemical-Inducible CRISPR-Cas Systems.
Liu KI; Ramli MNB; Sutrisnoh NB; Tan MH
Methods Mol Biol; 2018; 1772():267-288. PubMed ID: 29754234
[TBL] [Abstract][Full Text] [Related]
12. Chimeric DNA-RNA Guide RNA Designs.
Lu S; Zhang Y; Yin H
Methods Mol Biol; 2021; 2162():79-85. PubMed ID: 32926379
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Genome Editing and its Potential Enhancement through CRISPR Guide RNA and Cas9 Modifications.
Batzir NA; Tovin A; Hendel A
Pediatr Endocrinol Rev; 2017 Jun; 14(4):353-363. PubMed ID: 28613045
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of single guide RNA transcription for efficient CRISPR/Cas-based genomic engineering.
Ui-Tei K; Maruyama S; Nakano Y
Genome; 2017 Jun; 60(6):537-545. PubMed ID: 28177825
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the CRISPR genome editing tool set.
Moon SB; Kim DY; Ko JH; Kim YS
Exp Mol Med; 2019 Nov; 51(11):1-11. PubMed ID: 31685795
[TBL] [Abstract][Full Text] [Related]
16. RNA-Targeting CRISPR-Cas Systems and Their Applications.
Burmistrz M; Krakowski K; Krawczyk-Balska A
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046217
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9 Technology in Translational Biomedicine.
Leonova EI; Gainetdinov RR
Cell Physiol Biochem; 2020 Apr; 54(3):354-370. PubMed ID: 32298553
[TBL] [Abstract][Full Text] [Related]
18. Advances in Industrial Biotechnology Using CRISPR-Cas Systems.
Donohoue PD; Barrangou R; May AP
Trends Biotechnol; 2018 Feb; 36(2):134-146. PubMed ID: 28778606
[TBL] [Abstract][Full Text] [Related]
19. Guide RNA engineering for versatile Cas9 functionality.
Nowak CM; Lawson S; Zerez M; Bleris L
Nucleic Acids Res; 2016 Nov; 44(20):9555-9564. PubMed ID: 27733506
[TBL] [Abstract][Full Text] [Related]
20. The rapidly advancing Class 2 CRISPR-Cas technologies: A customizable toolbox for molecular manipulations.
Wang J; Zhang C; Feng B
J Cell Mol Med; 2020 Mar; 24(6):3256-3270. PubMed ID: 32037739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
